文献速递消化系统肿瘤

非V600 BRAF突变定义转移性结直肠癌的一种临床独特分子亚型

Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer.
PubMed 文献 · J Clin Oncol · 2017-05-09

这项多中心回顾性队列研究从三个大型分子遗传学参考实验室的二代测序(NGS)数据库中筛选出208例携带非V600 BRAF突变的转移性结直肠癌(CRC)患者,占全部受检患者的2.2%、全部BRAF突变的22%。与V600E BRAF突变相比,非V600 BRAF突变患者更年轻、女性更少、高分级肿瘤和右半原发肿瘤更少,中位总生存显著更长(60.7个月 vs 11.4个月 vs 43.0个月,P<.001),多变量分析中非V600 BRAF突变独立与总生存改善相关(HR 0.18,P<.001)。

要点

  • 非V600 BRAF突变见于约2.2%的转移性CRC患者,占全部BRAF突变的22%。
  • 非V600 BRAF突变患者中位总生存60.7个月,V600E为11.4个月,野生型为43.0个月(P<.001)。
  • 多变量分析中非V600 BRAF突变独立与总生存改善相关(HR 0.18,P<.001)。

核心结论

  • 非V600 BRAF突变发生于约2.2%的转移性CRC患者,定义了一种预后极好的临床独特CRC亚型。

研究设计与样本

  • 多中心回顾性队列研究,从三个大型分子遗传学参考实验室的NGS数据库中汇总非V600 BRAF突变患者。
  • 共9,643例转移性CRC患者接受NGS检测,其中208例检出非V600 BRAF突变。

主要发现

  • 非V600 BRAF突变占全部受检患者的2.2%,占全部BRAF突变的22%。
  • 与V600E BRAF突变相比,非V600 BRAF突变患者显著更年轻(58岁 vs 68岁),女性更少(46% vs 65%)。
  • 与V600E BRAF突变相比,非V600 BRAF突变患者高分级肿瘤更少(13% vs 64%),右半原发肿瘤更少(36% vs 81%)。
  • 中位总生存:非V600 BRAF突变60.7个月 vs V600E BRAF突变11.4个月 vs 野生型BRAF 43.0个月(P<.001)。
  • 多变量分析中,非V600 BRAF突变独立与总生存改善相关(HR 0.18,P<.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Molecular diagnostic testing has become an integral part of the evaluation of patients with metastatic colorectal cancer (CRC). Expanded mutational testing, such as next-generation sequencing (NGS), often identifies mutations with unclear clinical or prognostic implications. One such example is BRAF mutations that occur outside of codon 600 (non-V600 BRAF mutations). Methods We conducted this multicenter, retrospective cohort study to characterize the clinical, pathologic, and survival implications of non-V600 BRAF mutations in metastatic CRC. We pooled patients in whom non-V600 BRAF mutations were identified from NGS databases at three large molecular genetics reference laboratories. Results A total of 9,643 patients with metastatic CRC underwent NGS testing. We identified 208 patients with non-V600 BRAF mutations, which occurred in 2.2% of all patients tested and accounted for 22% of all BRAF mutations identified. Cancers with non-V600 BRAF mutations, compared with cancers with V600E BRAF (V600E BRAF) mutations, were found in patients who were significantly younger (58 v 68 years, respectively), fewer female patients (46% v 65%, respectively), and patients who had fewer high-grade tumors (13% v 64%, respectively) or right-sided primary tumors (36% v 81%, respectively). Median overall survival was significantly longer in patients with non-V600 BRAF-mutant metastatic CRC compared with those with both V600E BRAF-mutant and wild-type BRAF metastatic CRC (60.7 v 11.4 v 43.0 months, respectively; P < .001). In multivariable analysis, non-V600 BRAF mutation was independently associated with improved overall survival (hazard ratio, 0.18; P < .001). Conclusion Non-V600 BRAF mutations occur in approximately 2.2% of patients with metastatic CRC and define a clinically distinct subtype of CRC with an excellent prognosis.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Jones JC, Renfro LA, Al-Shamsi HO, et al. Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. J Clin Oncol. 2017. PMID: 28486044. doi:10.1200/JCO.2016.71.4394

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。